What Tecsomed does

Tecsomed is a privately held, pre-launch health technology company developing the myPOM platform, an integrated ecosystem for managing juvenile (Type 1) diabetes. The platform is intended to combine four components: a connected wearable communicator worn by the child, a parental smartphone application for real-time monitoring and alerts, a web portal for data-driven insights, and a lifestyle management module covering behavioral support and disease education. The company states that predictive analytics will be applied to real-time data for early intervention and risk identification, though no technical detail on model architecture, validation, or regulatory clearance has been disclosed.

Tecsomed's go-to-market posture is direct-to-consumer, targeting parents and caregivers of children with Type 1 diabetes who need continuous monitoring and remote communication tools. The planned business model is a recurring subscription for the myPOM platform bundled with the wearable device, though pricing, contract structure, and unit economics are not publicly disclosed. The website remains in a pre-launch state with a mailing list signup for release date updates and a generic contact form, indicating that no commercial product is currently shipping and no revenue is being recognized.

The company is incorporated in the United States, headquartered in Miami Beach, Florida, and operates with a 1-10 person team. No funding rounds, institutional investors, named customers, management team, regulatory submissions, or strategic partnerships are documented in the available data. Market context cited by the company includes 1.25 million Americans with Type 1 diabetes and an associated $14.9 billion in annual US healthcare costs, which frames the addressable opportunity but does not substitute for traction evidence.

Name

Tecsomed

Legal name

Tecsomed

Website

https://tecsomed.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Tecsomed is a pre-launch, privately held US health-tech company building the myPOM platform — a connected wearable, parental app, web portal, and lifestyle management module — to help parents of children with juvenile (Type 1) diabetes monitor and manage the condition in real time.

Ownership category

akta.pro rank

Product category

Digital Health Platform

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)

akta.pro secondary industries

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK)

Keywords

• Diabetes management platform
• Wearable health monitoring
• Juvenile diabetes care
• Predictive health analytics
• Remote patient monitoring

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. myPOM Platform Subscription: The company offers the myPOM platform as a comprehensive diabetes management solution, likely through a subscription model involving the wearable device and ongoing software access. Details not publicly disclosed.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Tecsomed develops the myPOM platform, an integrated juvenile diabetes management ecosystem that combines a connected wearable communicator device worn by the child, a parental smartphone application, a web portal, and a lifestyle management module. The platform leverages predictive analytics on real-time data to enable early risk identification, intervention, behavioral management, and disease education for children with Type 1 Diabetes and their parents/caregivers.

Product overview

Tecsomed offers the MyPOM platform, a unified diabetes management ecosystem for Juvenile Diabetes consisting of four integrated components: a wearable communicator device worn by the child, a parental smartphone app for real-time monitoring and alerts, a web portal for comprehensive data access, and a lifestyle management module for ongoing disease education and behavioral management. The platform leverages predictive analytics to identify potential risks and enable proactive intervention while facilitating communication between parents and children.

Differentiator

Problem solved

Functional benefit

Brands

• myPOM: Comprehensive diabetes management platform including myPOM Wearable Communicator, myPOM Lifestyle Management, myPOM Parental Smartphone App, and myPOM Web Portal for managing Juvenile Diabetes.

Products and services

• myPOM Platform (Integrated Juvenile Diabetes Management Ecosystem) Integrated platform for pediatric Type 1 Diabetes management combining wearable, mobile, web, and analytics components for continuous monitoring, parental communication, predictive intervention, and disease education.
• myPOM Wearable Communicator Child-friendly connected wearable for instant communication, location, and continuous monitoring in children with Juvenile Diabetes.
• myPOM Parental Smartphone App Smartphone application for parents providing real-time monitoring, alerts, and remote visibility into a child's diabetes metrics via the myPOM wearable.
• myPOM Web Portal Web-based dashboard for parents, caregivers, and clinicians providing data-driven insights, longitudinal views, and care coordination tools for pediatric diabetes management.
• myPOM Lifestyle Management Lifestyle and behavioral management module for ongoing disease education, behavioral support, and maintenance activities for children with Juvenile Diabetes and their families.

Quantifiable outcome

• Reduced healthcare costs through better diabetes management and early intervention

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Scale indicators3 records

Recent moves3 records

Expansion highlights4 records

Direct peers

• Dexcom: Market-leading continuous glucose monitor (CGM) manufacturer with FDA-cleared pediatric indications. Both Dexcom and Tecsomed target real-time glucose and lifestyle monitoring for diabetes patients, though Dexcom is an established clinical device.
• Abbott Diabetes Care: Maker of FreeStyle Libre CGM, including pediatric versions. Directly comparable as a glucose-monitoring wearable for diabetes with recurring sensor revenue, competing for the same caregiver-driven purchase decisions in T1D households.
• Medtronic Diabetes: Provides Guardian CGM and MiniMed insulin pump systems with pediatric use. Like Tecsomed, targets families managing juvenile diabetes, but with full closed-loop (hybrid closed-loop) systems and deep payor coverage.
• Insulet Corporation: Maker of the Omnipod tubeless insulin pump, widely used in pediatric T1D. Comparable because both companies sell wearable diabetes hardware paired with mobile/web software for caregivers managing children with diabetes.
• Tandem Diabetes Care: Produces the t:slim X2 insulin pump with Control-IQ technology integrated with CGMs. Similar positioning around real-time data, mobile control, and pediatric diabetes management for parents and caregivers.
• Glooko: Diabetes data management platform that aggregates data from CGMs, pumps, and wearables into a unified dashboard for patients and clinicians. Closest software peer to myPOM's web-portal and predictive-analytics layer.
• mySugr (Roche): Consumer diabetes self-management app with logging, bolus estimation, and caregiver features, now part of Roche. Comparable as a smartphone/web companion to CGM/wearables for daily diabetes lifestyle management.

Emerging players

• Tidepool: Nonprofit diabetes data platform integrating pumps, CGMs, and apps for patients and clinicians, with strong pediatric and parent-facing tooling. Comparable as a data-driven diabetes management layer for caregivers.
• Bigfoot Biomedical: Developer of smart insulin pen systems and a connected diabetes management platform. Comparable as a digitally enabled diabetes management ecosystem targeting simplified decision support for patients and caregivers.
• Senseonics (Eversense): Maker of the Eversense implantable long-term CGM with a配套 mobile app for continuous monitoring. Comparable as a wearable, connected, caregiver-visible diabetes monitoring solution, though with a more invasive form factor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/tecsomed
• Facebookfacebook.com/tecsomed
• LinkedInlinkedin.com/company/tecsomed

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tecsomed